Quarterly ResultApr 29, 2026, 04:37 PM
CBIO Q1 Net Loss $(23.3)M; Cash $189.2M; R&D Expenses Up
AI Summary
Crescent Biopharma, Inc. reported a net loss of $(23.3) million for Q1 2026, an increase from $(15.1) million in Q1 2025, as research and development expenses rose to $17.9 million. The clinical-stage biotechnology company ended the quarter with $189.2 million in cash and cash equivalents, expecting this to fund operations for at least twelve months. The company continues to incur significant operating losses and negative cash flows from operations, with an accumulated deficit of $(195.1) million.
Key Highlights
- Q1 2026 net loss was $(23.3) million, compared to $(15.1) million in Q1 2025.
- Cash and cash equivalents totaled $189.2 million as of March 31, 2026.
- Research and development expenses increased to $17.9 million in Q1 2026.
- General and administrative expenses rose to $7.9 million in Q1 2026.
- Accumulated deficit reached $(195.1) million as of March 31, 2026.
- Net cash used in operating activities was $(8.9) million in Q1 2026.
- Existing cash expected to fund operations for at least 12 months.
- Completed $185.0 million PIPE financing in December 2025.
Price Impact
More from CBIO